Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 206Neoplasms 191Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 89Prostatic Neoplasms 78Lung Neoplasms 73Multiple Myeloma 49Head and Neck Neoplasms 47Melanoma 46Pancreatic Neoplasms 43Neoplasm Metastasis 42Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 40Recurrence 34Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Ovarian Neoplasms 31Glioblastoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Glioma 27Uterine Cervical Neoplasms 26Sarcoma 26Lymphoma, Non-Hodgkin 26Lymphoma 26Stomach Neoplasms 25Lymphoma, Follicular 24Carcinoma, Renal Cell 24Esophageal Neoplasms 22Colonic Neoplasms 22Rectal Neoplasms 21

Interventions

Random Allocation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoid Tumors, Intestinal × 90 days × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡